Cargando…

Natural History and Genotype–Phenotype Correlation in Female X-Linked Alport Syndrome

INTRODUCTION: X-linked Alport syndrome (XLAS) is a hereditary disease characterized by progressive nephritis, hearing loss, and ocular abnormalities. Affected male patients usually progress to end-stage renal disease in early or middle adulthood, and disease severity is strongly correlated with geno...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamura, Tomohiko, Nozu, Kandai, Fu, Xue Jun, Nozu, Yoshimi, Ye, Ming Juan, Shono, Akemi, Yamanouchi, Satoko, Minamikawa, Shogo, Morisada, Naoya, Nakanishi, Koichi, Shima, Yuko, Yoshikawa, Norishige, Ninchoji, Takeshi, Morioka, Ichiro, Kaito, Hiroshi, Iijima, Kazumoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733817/
https://www.ncbi.nlm.nih.gov/pubmed/29270492
http://dx.doi.org/10.1016/j.ekir.2017.04.011
Descripción
Sumario:INTRODUCTION: X-linked Alport syndrome (XLAS) is a hereditary disease characterized by progressive nephritis, hearing loss, and ocular abnormalities. Affected male patients usually progress to end-stage renal disease in early or middle adulthood, and disease severity is strongly correlated with genotype. However, the clinical course in female patients has rarely been reported. METHODS: We conducted a retrospective analysis of females with genetically proven XLAS (n = 275) and their affected female family members (n = 61) from 179 Japanese families. Patients suspected to have Alport syndrome from pathologic findings or a family history who were referred from anywhere in Japan for genetic diagnosis between 2006–2015 were included in this study. Clinical and laboratory data were collected from medical records at the time of registration for genetic analysis. RESULTS: Proteinuria was detected in 175 genetically proven patients (72.6%), and the median age for developing proteinuria was 7.0 years. Fifty-two of 336 patients developed end-stage renal disease with a median renal survival age of 65.0 years. No obvious genotype–phenotype correlation was observed. Additionally, targeted sequencing for podocyte-related genes in patients with severe phenotypes revealed no obvious variants considered to be modifier genes except for 1 patient with a COL4A3 gene variant. DISCUSSION: This study revealed that phenotypes in female XLAS patients may be severe, but genotype does not help to predict the disease severity. Clinicians must therefore pay careful attention to the clinical course and appropriate treatment in females with XLAS.